These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 29892522)
1. Blockade of CCL2 enhances immunotherapeutic effect of anti-PD1 in lung cancer. Wang Y; Zhang X; Yang L; Xue J; Hu G J Bone Oncol; 2018 Jun; 11():27-32. PubMed ID: 29892522 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of IL-18-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy against osteosarcoma cancer. Guan Y; Zhang R; Peng Z; Dong D; Wei G; Wang Y J Bone Oncol; 2017 Nov; 9():59-64. PubMed ID: 29226090 [TBL] [Abstract][Full Text] [Related]
3. Blockade of CCR5-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy in gastric cancer. Yang L; Wang B; Qin J; Zhou H; Majumdar APN; Peng F Immunopharmacol Immunotoxicol; 2018 Feb; 40(1):91-97. PubMed ID: 29303012 [TBL] [Abstract][Full Text] [Related]
4. Myeloid-derived suppressor cell accumulation in renal cell carcinoma is correlated with CCL2, IL-17 and IL-18 expression in blood and tumors. Guan X; Liu Z; Zhang J; Jin X Adv Clin Exp Med; 2018 Jul; 27(7):947-953. PubMed ID: 29905412 [TBL] [Abstract][Full Text] [Related]
5. Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α. Najjar YG; Rayman P; Jia X; Pavicic PG; Rini BI; Tannenbaum C; Ko J; Haywood S; Cohen P; Hamilton T; Diaz-Montero CM; Finke J Clin Cancer Res; 2017 May; 23(9):2346-2355. PubMed ID: 27799249 [No Abstract] [Full Text] [Related]
6. PRPS2-mediated modulation of the antitumor immune response in lung cancer through CCL2-mediated tumor-associated macrophages and myeloid-derived suppressor cells. Liu Q; Wu N; Hou P Thorac Cancer; 2024 Aug; 15(23):1739-1748. PubMed ID: 38952044 [TBL] [Abstract][Full Text] [Related]
7. (3R)-5,6,7-trihydroxy-3-isopropyl-3-methylisochroman-1-one enhanced the therapeutic efficacy of anti-PD1 antibody through inhibiting PI3Kδ/γ. Cao L; Dai C; Qin R; Guo Y; Liu J Immunopharmacol Immunotoxicol; 2019 Dec; 41(6):599-606. PubMed ID: 31691624 [No Abstract] [Full Text] [Related]
8. [Myeloid-derived suppressor cell expression and significance in peripheral blood and tongue lesions of mouse]. Mei C; Guiqing L; Wen T; Yuan Z; Yuxiong S; Yujie L Hua Xi Kou Qiang Yi Xue Za Zhi; 2015 Dec; 33(6):575-80. PubMed ID: 27051947 [TBL] [Abstract][Full Text] [Related]
10. (-)-4-O-(4-O-β-D-glucopyranosylcaffeoyl) Quinic Acid Inhibits the Function of Myeloid-Derived Suppressor Cells to Enhance the Efficacy of Anti-PD1 against Colon Cancer. Lin H; Wu Y; Chen J; Huang S; Wang Y Pharm Res; 2018 Jul; 35(9):183. PubMed ID: 30062658 [TBL] [Abstract][Full Text] [Related]
11. Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy. Chen HM; Ma G; Gildener-Leapman N; Eisenstein S; Coakley BA; Ozao J; Mandeli J; Divino C; Schwartz M; Sung M; Ferris R; Kao J; Wang LH; Pan PY; Ko EC; Chen SH Clin Cancer Res; 2015 Sep; 21(18):4073-4085. PubMed ID: 25922428 [TBL] [Abstract][Full Text] [Related]
12. Yeast-Derived Particulate β-Glucan Treatment Subverts the Suppression of Myeloid-Derived Suppressor Cells (MDSC) by Inducing Polymorphonuclear MDSC Apoptosis and Monocytic MDSC Differentiation to APC in Cancer. Albeituni SH; Ding C; Liu M; Hu X; Luo F; Kloecker G; Bousamra M; Zhang HG; Yan J J Immunol; 2016 Mar; 196(5):2167-80. PubMed ID: 26810222 [TBL] [Abstract][Full Text] [Related]
13. T cells conditioned with MDSC show an increased anti-tumor activity after adoptive T cell based immunotherapy. Raber PL; Sierra RA; Thevenot PT; Shuzhong Z; Wyczechowska DD; Kumai T; Celis E; Rodriguez PC Oncotarget; 2016 Apr; 7(14):17565-78. PubMed ID: 27007050 [TBL] [Abstract][Full Text] [Related]
14. Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer. Idorn M; Køllgaard T; Kongsted P; Sengeløv L; Thor Straten P Cancer Immunol Immunother; 2014 Nov; 63(11):1177-87. PubMed ID: 25085000 [TBL] [Abstract][Full Text] [Related]
15. Circulating Myeloid-Derived Suppressor Cell Subsets in Patients with Colorectal Cancer - Exploratory Analysis of Their Biomarker Potential. Fědorová L; Pilátová K; Selingerová I; Bencsiková B; Budinská E; Zwinsová B; Brychtová V; Langrová M; Šefr R; Valík D; Zdražilová Dubská L Klin Onkol; 2018; 31(Suppl 2):88-92. PubMed ID: 31023030 [TBL] [Abstract][Full Text] [Related]
16. The Yin/Yan of CCL2: a minor role in neutrophil anti-tumor activity in vitro but a major role on the outgrowth of metastatic breast cancer lesions in the lung in vivo. Lavender N; Yang J; Chen SC; Sai J; Johnson CA; Owens P; Ayers GD; Richmond A BMC Cancer; 2017 Jan; 17(1):88. PubMed ID: 28143493 [TBL] [Abstract][Full Text] [Related]
17. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy. Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008 [TBL] [Abstract][Full Text] [Related]
18. [Variation of subsets of myeloid derived suppressor cells and their ratio in septic mice]. Wang H; Zhao Q; Huang Z; Zhao M; Xu X Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2016 Feb; 28(2):147-52. PubMed ID: 26911947 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies. Hossain F; Al-Khami AA; Wyczechowska D; Hernandez C; Zheng L; Reiss K; Valle LD; Trillo-Tinoco J; Maj T; Zou W; Rodriguez PC; Ochoa AC Cancer Immunol Res; 2015 Nov; 3(11):1236-47. PubMed ID: 26025381 [TBL] [Abstract][Full Text] [Related]
20. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Lu X; Horner JW; Paul E; Shang X; Troncoso P; Deng P; Jiang S; Chang Q; Spring DJ; Sharma P; Zebala JA; Maeda DY; Wang YA; DePinho RA Nature; 2017 Mar; 543(7647):728-732. PubMed ID: 28321130 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]